Company news

Agios Pharmaceuticals, Inc. news in 2025

Agios Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

December 22, 2025

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

December 7, 2025

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

November 18, 2025

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

November 2, 2025

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

October 29, 2025

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

October 16, 2025

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8: 00 a.m. ET

October 15, 2025

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

September 3, 2025

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

August 3, 2025

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

July 30, 2025

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8: 00am ET

July 13, 2025

Agios Appoints Dr. Jay Backstrom to Board of Directors

July 7, 2025

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 27, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 13, 2025

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 8, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 1, 2025

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

April 30, 2025

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

April 16, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

March 4, 2025

Agios to Present at Upcoming Investor Conferences

March 3, 2025

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

February 19, 2025

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 12, 2025

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

February 12, 2025

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

February 5, 2025

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

January 12, 2025

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

January 7, 2025

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

January 7, 2025

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

January 2, 2025

Calls in 2025

Decks in 2025